• 1. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzisoxazoles

Introduction to 3-(3-Bromophenyl)benzo[d]isoxazole (CAS No. 99763-25-4)

3-(3-Bromophenyl)benzo[d]isoxazole, identified by its Chemical Abstracts Service (CAS) number 99763-25-4, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic aromatic structure has garnered attention due to its unique molecular framework and potential biological activities. The presence of both bromine and isoxazole moieties in its chemical composition makes it a versatile scaffold for further derivatization and functionalization, which has been exploited in various synthetic and pharmacological studies.

The compound belongs to the benzo[d]isoxazole class, a family of molecules known for their broad spectrum of biological interactions. Specifically, the 3-bromophenyl substituent introduces a region of electrophilic character, making it amenable to nucleophilic substitution reactions. This feature has been leveraged in the development of novel intermediates for drug discovery programs. Furthermore, the benzo[d]isoxazole core is structurally related to several bioactive natural products and pharmacologically relevant molecules, suggesting that derivatives of this compound may exhibit similar therapeutic properties.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various disease pathways. Among these, kinases have emerged as critical therapeutic targets due to their involvement in numerous cellular processes, including cell proliferation, differentiation, and apoptosis. 3-(3-Bromophenyl)benzo[d]isoxazole has been explored as a potential scaffold for kinase inhibitors, particularly those targeting tyrosine kinases. Its rigid aromatic system provides a suitable platform for designing molecules with high binding affinity and selectivity.

One of the most compelling aspects of 3-(3-Bromophenyl)benzo[d]isoxazole is its adaptability in medicinal chemistry libraries. The bromine atom at the 3-position of the phenyl ring serves as a handle for further chemical modifications, such as Suzuki-Miyaura cross-coupling reactions, which can introduce aryl or heteroaryl groups at various positions along the molecule. These modifications have led to the synthesis of numerous analogs with enhanced pharmacological profiles. For instance, researchers have reported the development of potent JAK2 inhibitors derived from this scaffold by incorporating additional functional groups that improve solubility and metabolic stability.

The pharmaceutical industry has long recognized the value of heterocyclic compounds in drug development. Benzo[d]isoxazole derivatives are particularly noteworthy due to their ability to modulate biological pathways associated with inflammation, cancer, and infectious diseases. 3-(3-Bromophenyl)benzo[d]isoxazole exemplifies this potential through its incorporation into various drug discovery campaigns. Its structural features allow for interactions with both protein and nucleic acid targets, making it a valuable building block for multitargeted therapeutics.

Recent advances in computational chemistry have further accelerated the design and optimization of molecules like 3-(3-Bromophenyl)benzo[d]isoxazole. Virtual screening techniques combined with molecular docking simulations have enabled researchers to predict binding affinities and optimize lead compounds with remarkable efficiency. These computational tools have been instrumental in identifying novel derivatives with improved potency against specific kinases or other therapeutic targets.

The synthesis of 3-(3-Bromophenyl)benzo[d]isoxazole itself is an elegant example of modern organic chemistry techniques. The process typically involves multi-step sequences that begin with the formation of the isoxazole ring followed by bromination at the phenyl substituent. Advances in catalytic methods have allowed for more efficient and sustainable synthetic routes, reducing waste and improving yields. Such improvements are crucial for large-scale production and commercialization efforts.

In addition to its applications in kinase inhibition research, 3-(3-Bromophenyl)benzo[d]isoxazole has been explored as an intermediate in the synthesis of other bioactive molecules. Its structural motif is reminiscent of several FDA-approved drugs used in treating conditions ranging from hypertension to depression. By leveraging this scaffold, chemists can generate libraries of compounds with tailored biological activities for preclinical testing.

The role of CAS No. 99763-25-4 as a reference point underscores its importance in academic and industrial research settings. Standardized identifiers like CAS numbers ensure clarity and consistency across scientific literature, facilitating collaboration between researchers worldwide. This compound’s well-documented properties make it an excellent candidate for teaching purposes as well as cutting-edge drug discovery initiatives.

Future directions in the study of 3-(3-Bromophenyl)benzo[d]isoxazole may include exploring its potential as an antimicrobial agent or investigating its effects on non-protein targets such as DNA or RNA interactors. The growing interest in modulating epigenetic mechanisms further expands possible applications for this versatile scaffold. As research continues to uncover new therapeutic opportunities, compounds like 99763-25-4 will undoubtedly play a pivotal role in shaping next-generation pharmaceuticals.

• 595566-87-3(1,2-Benzisoxazol-6-ol, 3-(5-bromo-6-hydroxy-2-naphthalenyl)-)
• 852160-48-6(5,5'-Bi-1,2-benzisoxazole, 3,3'-diphenyl-)
• 402914-15-2(5-BROMO-3-PHENYLBENZO[D]ISOXAZOLE)
• 87828-91-9(1,2-Benzisoxazole, 3-(2,6-dimethylphenyl)-)
• 7007-67-2(1,2-Benzisoxazole, 3-phenyl-)
• 13484-04-3(3-(4-Bromophenyl)isoxazole)
• 1428881-25-7(7-Bromo-3-phenylbenzo[D]isoxazole)
• 66639-61-0(1,2-Benzisoxazole-5-carbonitrile, 3-(4-cyanophenyl)-)
• 99763-22-1(3-(2-Bromophenyl)benzo[d]isoxazole)
• 620971-08-6